Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 11201 - 11208 of 12007 results

Don't Hate Me 'Cause I'm Beautiful: Termination Based on "Irresistible Attraction" is Not Unlawful Sex Discrimination
January 4, 2013| Blog| Viewpoint

Fiscal Cliff Bill Includes Commuter Tax Benefits
January 4, 2013| Blog| Viewpoint

FCC Establishes New Healthcare Connect Fund
January 4, 2013| Advisory| Viewpoint

Words of Warning: "No breach too small"
January 4, 2013| Blog| Viewpoint

First OCR Resolution for Data Breach Involving Less than 500 Patients: No Breach is “Too Small”
January 3, 2013| Blog| Viewpoint

First of a series (updated): Issues for 2013
January 3, 2013| Blog| Viewpoint

Late Action To Avert “Fiscal Cliff” Includes Several Health Policy Changes
January 3, 2013| Alert| Viewpoint

New FINRA Rule 5123 Regarding Private Placements of Securities Effective December 3, 2012
January 2, 2013| Alert| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
